DMII — Drugs Made In America Acquisition II Corp. Ordinary Shares stock price, charts and financials

QT56Drugs Made In America Acquisition II Corp. Ordinary Shares

NASDAQ·Financial Services·Shell Companies·USA

Latest market price

10.11

+0.00%

Overview Short InterestFilings

DMIIQT56Drugs Made In America Acquisition II Corp. Ordinary Shares·NASDAQ

Overview Short InterestFilings

10.11+0.00%

Loading chart...

Screen all →

CCXI-0.45%$15.40 NWAX+0.20%$10.15 KRSP+0.38%$10.50 BCSS+0.00%$10.21 CEPF+0.10%$10.41 CRAN+0.20%$10.16 ANSC+0.00%$11.45 GTEN-0.29%$10.45

Snapshot

Index	-	P/E	0.60	EPS (ttm)	16.93	Insider Own	0.47%	Shs Outstand	63.70M	Perf Week	0.00%

Market Cap	644.01M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	49.59M	Perf Month	0.20%

Enterprise Value	644.01M	PEG	0.00	EPS next Q	-	Inst Own	-	Short Float	0.09%	Perf Quarter	0.90%

Income	4.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	0.37	Perf Half Y	1.40%

Sales	0.00	P/B	1.32	EPS next Y	-	ROA	1.68%	Short Interest	46.51K	Perf YTD	2.12%

Book/sh	7.65	P/C	-	EPS next 5Y	-	ROE	2.35%	52W High	10.20 -0.88%	Perf Year	-

Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	-	ROIC	-0.27%	52W Low	9.86 2.54%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	0.10% 0.15%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-	Oper. Margin	0.00%	ATR (14)	0.02	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	0.53	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	58.00	Recom	-

Dividend Gr. 3/5Y	-	Current Ratio	0.53	EPS Q/Q	-	SMA20	0.11%	Beta	-0.01	Target Price	-

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	0.24%	Rel Volume	0.00	Prev Close	10.11

Employees	2	LT Debt/Eq	-	Earnings	-	SMA200	1.07%	Avg Volume	91.04K	Price	10.11

IPO Date	Dec 04, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-	Net Debt/EBITDA	-0.08	Volume	405	Change	0.00%

Company

Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024
Total Revenue	0	0
Cost of Goods Sold Incl. D&A	0	0
Gross Profit	0	0
Selling, General and Administrative Excl. Other	0	0
Research and Development	0	0
Other Operating Expense	1	0
Operating Income	-1	0
Interest Expense	0	0
Unusual Expense	—	—
Non-Operating Income (Expense)	5	0
Net Income Before Taxes	4	0
Income Taxes	0	0
Consolidated Net Income	4	0
Net Income From Continuing Operations	4	0
Net Income	4	0
EPS (Recurring)	0.16	-0.00
EPS (Basic, Before Extraordinaries)	0.16	-0.00
EPS (Diluted)	0.15	-0.00
EBITDA	-1	0
Other After Tax Adjustments	—	—
Stock Option Compensation Expense	—	—
Price To Earnings Ratio	66.00	—
Price To Sales Ratio	—	—
Gross Margin	—	—
Operating Margin	—	—
Net Margin	—	—
Shares Outstanding	13	64
Market Capitalization	129	—
Operating Lease Expense	—	—

Insider Trading Volume

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.